Research programme: CNS disorders therapeutics - AbbVie

Drug Profile

Research programme: CNS disorders therapeutics - AbbVie

Alternative Names: Neuroscience programme - Solvay; SLV326; SLV347; SLV351; SLV353; SLV355; SLV357; SLV359; SLV360

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solvay
  • Developer AbbVie
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported CNS disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in European Union
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 29 Apr 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top